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Survival from head and neck squamous cell carcinoma (HNSCC) has remained static for the last 20 years. The development of lymph
node metastasis (LNM) significantly reduces the 5-year survival rate, thus the ability to identify tumours with the potential to
metastasise would allow more aggressive treatment regimes to be directed at these patients regardless of negative clinical and
radiological findings at the time of presentation. Comparative genomic hybridisation (CGH) can identify chromosomal aberrations
that may lead to metastasis. DNA from 23-paired specimens of primary tumour (PT) and LNM were analysed. Nonrandom copy
number changes were identified in all paired samples. Similar numbers of aberrations were identified on PT and LNM samples. The
most common aberrations were 3q (90%), 8q (65%), 1q (50%), 5p (43%), 2q (41%) and 11q (41%) and deletions 3p (57%), 1p
(54%), 4p (48%), 13q (48%), 11q (41%) and 10q (37%). A number of differences were also detected. No aberration was found to be
preferentially associated with the LNM, although gains on 6q (48 vs 22%) and 22q (26 vs 9%) were found at higher frequencies.
Clonality studies demonstrated that LNM develop from the dominant population of cells in the PT. These results were compared
with two similar publications. No combination of chromosomal aberrations, as detected by CGH, was associated with metastatic
progression in HNSCC.
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Head and neck squamous cell cancer (HNSCC) is a major health
problem worldwide accounting for significant morbidity and
mortality. The survival rate over the last 20 years has not improved
appreciably despite a number of new and refined treatment
modalities. Although many different prognostic indicators have
been studied, the occurrence of nodal metastasis at presentation
remains the single most important factor, decreasing the 5-year
survival rate from approximately 75 to 29% (Ono, 1986). The
identification of tumours with metastatic potential prior to the
occurrence of detectable nodal spread would allow more aggressive
primary treatment regimes to be instigated and directed at regional
as well as local control.
Genetic studies have begun to characterise the chromosomal
abnormalities involved in HNSCC. However, relatively little is
known about the genetic aberrations associated with the metastatic
event. Comparative genomic hybridisation (CGH) is a powerful
technique that screens the entire genome for regions of DNA
sequence copy number alterations. Comparative genomic hybri-
disation has previously been applied in several HNSCC studies and
has demonstrated a nonrandom pattern of genomic aberrations
commonly showing deletions of material from 3p, 4q, 5q, 9p, 18q
and gains involving 3q, 5p, 7p, 8q, 11q, 17q and 20q (Struski et al,
2002). Although a number of tumour progression models have
been constructed, based on the frequency of these aberrations
(Bockmuhl et al, 2002; Huang et al, 2002), there has been no clear
pattern of mutations that lead to metastasis.
An additional level of complexity is found in HNSCC due to the
coexistence of karyotypically unrelated clones (Veltman et al, 1998;
Jin et al, 2002). The presence of multiple clones with differing
phenotypic characteristics within the primary can make identifica-
tion and analysis of the metastatically competent cells very
difficult.
Only a few studies have looked at the direct comparison between
complete karyotypes of HNSCC primary tumour (PT) and the
related lymph node metastases (LNM) (Kujawski et al, 1999;
Bockmuhl et al, 2002). Kujawski et al (1999) compared data from
CGH analysis of 19 paired laryngeal SCC PT and LNM. Out of 17
analysed pairs, the most common copy number changes on both
primary tumour and metastasis were found on 3p, 3q, 5p, 9 and 13.
Losses on chromosomes 13, 8p and 9q were found more frequently
on the LNM than the PT. Welkoborsky et al (2000) analysed 20
patient–10 node-negative and 10 node-positive (both primary and
lymph node samples) oropharyngeal and hypopharyngeal squa-
mous cell carcinoma (SCC). Over-representations, as defined
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sby these authors, of 21q and 22q were found in both PT and LNM.
Gains of 1q, 8q, 11q, 18q and 19p were more frequent in the LNM,
whereas a gain on 11p and a loss on 17p were only found in the
LNM. Unfortunately, the results from Welkoborsky et al (2000)
could not be used for comparative purposes, as the raw data were
not shown in the publication. Bockmuhl et al (2002) investigated
54 patients: 34 matched HNSCC pairs and 20 nonmetastasising
HNSCC samples. The clonal relationship between the PT and LNM,
that is, evidence of the LNM originating from the PT was evaluated
using three mathematical models, revealing concordance in 64–
68% of the matched pairs. Of the paired samples, gains on 11q13,
7q11.2, 1q21–q22 and deletions on 8p, 11p14-qter, 10p12, 10q and
14 were associated with metastasis. Owing to the relatively low
numbers of matched HNSCC (PT and LNM) that have been
analysed, we describe the second largest cohort of CGH data for
primary HNSCC and their corresponding lymph nodes. The
possibility of identifying potential genetic aberrations that lead
to metastasis is discussed after combining our data with the results
of the two previous studies.
MATERIALS AND METHODS
Tissue samples
Tissue samples were collected from 23 patients (17 male and six
female) undergoing surgery for HNSCC at the Department of
Otolaryngology and Head and Neck Surgery, Hull Royal Infirmary
between 1997 and 2002. All biopsies were collected from patients
undergoing composite resections for oral cavity and oropharyn-
geal tumours, or total laryngectomy with or without partial
pharyngectomy for tumours of the laryngopharynx. In each case,
the LNM and primary biopsy were taken at the same time and no
second primary was evident in any of the cases. There was neither
a history of previous malignancy nor had any of the patients
received treatment prior to surgical resection. A consultant
pathologist (A.M) confirmed all samples to be SSC and all tumours
were staged according to UICC guidelines. The Hull and East
Yorkshire Research Ethics Committee approved the study and
informed, written consent was obtained from all patients. Samples
were immediately snap frozen in liquid nitrogen at the time of
resection and stored at  801C. The clinicopathological details of
all patients are summarised in Table 1. For each sample, a 10mm
tissue section was cut adjacent to the extracted section. These were
stained with haematoxylin and eosin to assess normal to tumour
cell ratio; greater than 70% tumour cell content was needed for
CGH analysis.
Comparative genomic hybridisation
DNA was extracted from 20 serial 20mm cryostat sections, or using
the whole biopsy by proteinase K digestion followed by phenol–
chloroform extraction. DNA quality and purity were assessed by
electrophoresis and spectrophotometry at 260nm and CGH
performed essentially as described previously (Stafford et al,
1999). All CGH reagents were obtained from Vysis Ltd (Maiden-
head, UK). All experiments were performed in combination with
both positive (DNA with known aberrations) and negative (normal:
normal hybridisation) control experiments. Sex mismatching of test
and reference DNA precluded the analysis of the sex chromosomes.
Deletions and gains of DNA were identified whenever the CGH ratio
profile exceeded thresholds established through normal: normal
hybridisations (0.85 and 1.15, respectively).
Analysis
The presence of each aberration was scored independently, that is,
gains and deletions were considered separately. Multiple gains or
deletions on the same arm were interpreted depending on the site,
size and amplification involved according to the guidelines in
Zitzelsberger et al, (1997) and Jeuken et al, (2002).
Clonal relationship
If the LNM originated from the dominant cell population within
the PT, similarities between the copy number changes and their
location would be expected. Based on this expectation, Alejandro
Schaffer developed a probabilistic model to quantify the asso-
ciation between two matched tumour samples (Kuukasjarvi
et al, 1997).
The occurrence of an aberration was weighted depending on its
frequency in the entire population. Aberrations common to both
paired samples could then be used to evaluate the clonality. ‘This
model uses only data from shared abnormalities and assumes that
the paired specimens must be both losses or both gains, and that
the breakpoint along the chromosome arm is the same’
(Kuukasjarvi et al, 1997).
Statistical analysis
If there is a clonal relationship between the two groups of
specimens, the occurrence of an aberration in the primary would
alter the expectation of its presence in the LNM, thus McNemar’s
test was applied to evaluate the significance of the individual
aberrations. w
2 or Fisher’s exact test, as appropriate, was also used
so that the comparison with other publications could be
performed.
RESULTS
Comparative genomic hybridisation analysis of our 46 samples
revealed a mean of 18 (range 5–36) and 19 (range 7–43)
aberrations in the PT and LNM, respectively. From these data, a
mean of 11 aberrations were found common to both samples. The
follow-up and survival data from these patients have been
discussed previously (Ashman et al, 2003).
Table 1 Patients clinicopathological details
Patient
no.
Age
(years) Tumour site T stage N stage Differentiation
1 58 Hypopharynx 4 2 Poor
2 53 Hypopharynx 4 3 Poor
3 55 Larynx 4 2c Poor
4 55 Hypopharynx 1 2 Poor
5 54 Oropharynx 4 1 Moderate
6 65 Larynx 3 1 Moderate
7 70 Larynx 2 1 Well
8 50 Hypopharynx 4 2b Poor
9 67 Hypopharynx 4 2 Poor
10 52 Larynx 4 2c Poor
11 71 Larynx 4 1 Moderate
12 57 Oropharynx 2 2 Poor
13 65 Oropharynx 4 2b Moderate
14 67 Hypopharynx 3 2a Poor
15 55 Hypopharynx 3 2a Moderate
16 61 Larynx 3 2b Poor
17 48 Larynx 3 1 Mod
18 65 Hypopharynx 2 2 Poor
19 44 Larynx 2 2 Moderate
20 72 Hypopharynx 4 1 Poor
21 56 Larynx 4 2 Poor
22 76 Larynx 4 2 Moderate
23 61 Larynx 4 2c Moderate
T stage¼tumour stage; N stage¼nodal stage.
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observed in 21 out of the 23 patients (91%), more precisely the loci
3q25–q27 in 20 of the 23 of the PT (87%), and 21 of the 23 LNM
(91%). Table 2 summarises the frequent aberrations, greater than
30% found in either or both of the matched specimens. For
comparison, the data from Bockmu ¨hl’s and Kujawski’s series are
included in Table 2.
A mean of seven and eight aberrations were found to be
unique to either PT or LNM, respectively. The most common
unique aberration found throughout the metastatic samples
was a gain on 6q present in nine of 23 (39%) lymph nodes.
This gain was found in four other lymph nodes, but also in
their relevant PT; two PT had unique aberrations on 6q. The
gains on 6q were further located to two independent loci, 6q13
and 6q22.3. A gain on 22q was unique to the LNM at a slightly
lower frequency–six of 23 (26%). One matched pair and one
PT independent of its lymph node expressed this aberration as
well. Other frequent findings unique to the lymph nodes
were gains on 1q, 7q, 13q and deletions on 1p. McNemar’s and
Fisher’s exact tests did not find any significant differences
between the expression of specific locations in either PT and
LNM genotypes.
The chromosomal locations of all of the aberrations are shown
in Tables 3 and 4. Figures 1 and 2 depict the location of all of the
chromosomal gains and losses found in our patients.
The clonal relationships (CR) between primaries and LNMs were
evaluated according to a probabilistic model. These results showed
a strong CR, 495% concordance in all but one case.
DISCUSSION
CGH screens the entire genome for DNA copy number alterations,
and thus yields vast quantities of information. Analysis of this
information from a matched primary tumour and lymph node
provides a clear picture of the presence or absence of a CR. In our
study, a strong CR was found in all but one case, strongly
suggesting that the cells, which were found in the lymph nodes,
originate from the dominant cell population in their correspond-
ing primary tumours.
Our cohort of patients was similar to Bockmu ¨hl’s series, that is,
all samples were HNSCC taken from patients with no history
of previous malignancy or treatment such as radiotherapy.
The cohort of 23 patients reported here is the second largest
group to be studied: Bockmu ¨hl’s series contained 34 patients.
Kujawski’s cohort (19 patients) matched the same patient
criteria but limited the site to larynx. Comparison of our findings
show that the frequency of 3q25–q27, 5p, 11q13–q14.1 and 1q31
gains are the same as reported previously (Bockmuhl et al,
1998; Bergamo et al, 2000; Gollin, 2001). Our results were also
very similar to Kujawski et al (1999) with respect to gains at
3q22–q24, 8q24 and deletions at 3p22–p25, 4p15.3-pter,
4q33-qter, 7q22 and 18q23. Bockmu ¨hl’s series (2000) revealed a
higher incidence of all these aberrations, which could be explained
by different and/or more sensitive CGH analysis software.
Interestingly, in our and Bockmu ¨hl’s cohort, aberrations were
found that were absent in Kujawski’s series, for example, deletions
at 1p34.2-pter (found in 43.5% of the PT and 39.1% of the
LNM in our cohort, and 65 and 27%, respectively, in Bockmu ¨hl’s
cohort) and 19p13.3-pter (found in 17.4% of PT samples and
30.4% of LNM in our cohort, and 15 and 63%, respectively, in
Bockmu ¨hl’s cohort). The significance of these differences is
unclear, but they seem to highlight the need for analysis of
specific subsites of HNSCC to clarify whether these genetic
variations reflect different anatomical locations and if so their
potential as diagnostic markers. This study, although reporting
one of the largest HNSCC cohorts, becomes relatively small
if subdivided by anatomical site or staging; therefore, such
analysis was not undertaken.
The similar number of unique random aberrations in both the
primary and LNM samples could be explained by continued clonal
evolution after the divergence of the metastatic cells. If this is the
case, the unique changes in the primary tumour are most likely to
be incidental to the metastatic progression. Therefore, the
common aberrations found in both paired samples as well as the
unique changes in the LNM probably underlie the tumour cell’s
ability to metastasise and proliferate.
Our data show associations between gains of chromosomal
material on 6q and 22q in the LNM and not in the primary
tumour samples. Detailed analysis of the location of the DNA
gain on 6q show two frequent areas –6q13 and 6q22.3, both
more frequent in the LNM than PT, but not of statistical
significance (P¼0.2 and 0.11, respectively). There were also
more LNM samples with gains of DNA material on 22q.
Bockmu ¨hl’s cohort (along with Welkoborsky et al, 2000) found
equal numbers of 22q aberrations between PT and LNM, whereas
Kujawski had very few in either sample (Table 2). Although
the difference in the expression of this gain on 22q was not
statistically significant in our cohort (McNemar’s test P¼0.07,
Fisher’s exact test P¼0.056), other studies have found a loss
of heterozygosity at this site (Poli-Frederico et al, 2000; dos
Reis et al, 2002) and an association with poor prognosis (Ashman
Table 2 Frequency of chromosomal aberrations found in greater than
30% of the specimens analysed
Frequency
(n¼23)
Bockmuhl
et al (2002)
(n¼34)
Kujawski
et al (1999)
(n¼17)
Location Gain/deletion % PT
%
LNM % PT
%
LNM % PT
%
LNM
3q26–27 Gain 78 87 80 85 59 71
3p25-pter Deletion 52 43 83 80 53 41
5q34-qter Deletion 52 39 50 70 6 12
1p34.2-pter Deletion 43 39 65 27 0 0
5p15.1-pter Gain 43 22 50 50 35 29
11q13.3–13.5 Gain 39 26 65 80 47 53
11q23.3 Deletion 39 30 65 58 21 32
12p12.3–13.1 Gain 39 26 40 50 29 12
2q31 Gain 39 35 60 48 6 6
3q24 Gain 39 65 80 60 41 35
8q21.3 Gain 39 30 50 50 0 18
8q23 Gain 39 57 60 80 6 18
18p11.31-pter Gain 35 26 23 20 0 5
3p14.1–3 Deletion 35 39 85 87 71 59
6q12 Gain 35 39 55 35 0 6
10q26.1-qter Deletion 30 35 45 38 5 5
13q31 Deletion 30 43 85 67 47 71
4p16 Deletion 30 43 55 60 29 35
8p22 Deletion 30 30 55 60 6 24
1q31 Gain 26 30 40 43 24 24
7q31.1–3 Gain 26 30 44 38 5 16
12q22 Gain 22 30 45 37 6 0
1q21.2 Gain 22 30 75 65 24 24
19p13.3-pter Deletion 17 30 15 63 0 0
4q26 Gain 17 30 77 27 0 0
4q34 Deletion 17 35 70 55 18 24
6q22 Gain 17 35 50 50 0 0
5q13 Deletion 13 35 69 75 32 37
9p24 Deletion 13 30 56 69 42 47
13q22 Gain 9 30 85 70 0 5
It should be noted that the percentage shown in Bockmu ¨hl’s series is the maximum
percentage found at any particular location read from the histogram provided on
http://amba.charite.de/cgh. PT¼primary tumour; LNM¼lymph node metastasis.
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each other: STMY3 at 22q11.2 and the BCR gene. The STMY3
gene encodes for stromelysin III, a member of the matrix
metalloproteinase family that is involved in the physiological
and pathological control of extracellular matrix remode-
lling. Stromelysin III has been found to be overexpressed in the
stromal cells of invasive breast carcinoma (Nakopoulou et al,
2002). Whether this chromosomal gain on 22q only occurred
in a few cells in the PT, and therefore, was not detectable by
CGH, but gave this subclone a competitive advantage to
metastasise or whether this expression occurred after migration
is not clear from this study. Future work focusing on such genes
in the PT will hopefully clarify their importance in the develop-
ment of metastasis.
The CGH results from our work and the previous two major
studies discussed here have upheld the clonality of the meta-
static cells; but no obvious single or group of aberrations
appears to cause metastatic spread in HNSCC, that is, a distinct,
common tumour progression pathway is not evident. It must be
noted that 18 of 23 of our cohort had advanced T3 or T4
carcinomas, and thus more incidental aberrations may be present
and obscure the genotype for metastatic progression. A similar
preponderance towards more advanced tumours is true for
Bockmuhl’s cohort.
Another theory is that some primaries are ‘preconfigured
to metastasise’ by the time of diagnosis (Ramaswamy et al,
2003). Both Welkoborsky et al (2000) and Bockmuhl et al
(2002) attempted to address the differences between nonmetasta-
sising and metastasising HNSCC in their studies; however,
disparate results have been reported. Welkoborsky and co-workers
reported over-representation of DNA on 1p and 7p exclusively
in node-negative PT and over-representation of DNA on 1q,
11q and 22q were in node-positive PT. Bockmuhl et al (1997)
analysed 29 metastasising and 19 nonmetastasising HNSCC,
and showed a preferential association between gain of DNA
on 5p, 6p and 7p and node-negative PT. Node-positive tumours
were characterised by deletions on chromosomes 7q, 10q 11p,
11q 15q and 20p, as well as gains on chromosomes 19q and
Table 3 Chromosomal locations of DNA gain in individual patients
ID
no. Both samples, common gains PT, unique gains
Total no.
gains LNM, unique gains
Total no.
gains
1 3q, 11q13 1q25-qter, 6p22, 8q21–23,12p 6 1p33–35, 16, 17, 18p, 19, 20q, 22 9
2 3q 7qcen-q32, 11q13, 18q11.2 4 1q21–32, 22q 3
3 1q21–31, 3q22-qter, 5p, 8q, 11p13–q22 5 4q13.1–13.3, 6qcen-23, 12q21.1–21.3, 22q 9
4 1q25–31 1 3q, 6q21, 8q22–24, 18q 5
5 1p22, 3q24-qter, 7q21–31.2, 11q13 6p22-pter 5 5p, 6qcen-15, 13q21–22 7
6 3q, 8, 12p11.2–q 23 5p, 7p15–q32, 13q14, 14qcen-q22,
16p11.2–12, 18p
9 1p22, 2q22–32, 4cen-q31, 5qcen-23,
6qcen-23, 9p21, 11p13, 13q21–31
11
7 7q11.2, 18q11.2 2 2p16, 2q22–q32, 3q25–q26, 4p14–q31,
5q21–q23, 6qcen-q23,12q21,13q2-q31
8
8 1qcen-q32, 3q, 5p, 8q, 11q22, 2q24.3, 9q, 12q21.3, 14q22–23 9 13q21 6
9 5pcen-p14, 7cen, 12p 3q25.2–q25.3 4 2q32.3, 6qcent-q12, 6q21–q22.3, 11q21 7
10 2q22–31, 3q24–26, 4qcen-q31, 6qcen-23,
8q, 12q21
1p31–22, 5p, 5q15–23, 11p14,
11q21–22, 13q, 18q12
13 6
11 2q22–q32, 3cen-q13, 3q24–q27, 8q,
12q21, 13q21
2p13–p16, 7q11.2, 12p 9 1p22, 4q, 5q21–22, 6qcen-q21, 9p21 11
12 3q 6qcen-q21 2 1p32–p35, 12p13, 16p, 17q12, 19q, 20q, 22 8
13 1pcen-p22, 2q22–32, 3q24-qter,
4cen-q25, 6qcen-q22, 12q15–21
8q21–23, 9q, 11p13, 14q13 10 13q21, 17q23-qter 8
14 3q24-qter, 5p, 6p22-pter, 8q,
13q31-qter,18
1q32-qter, 6qcen-q16 8 5q34-qter, 7q11.2, 15cen-q14, 20p 10
15 3q24–q28, 4qcen-q21.1, 5p, 8q23,
13q21.2–q21.3, 18p11.31-pter,
22q12.2–q13.2
2p, 4p16-pter, 7p21, 12p,
16p13.2-pter, 17p13-pter
13 20q13.2 8
16 1q, 2p13–p21, 2q24–q32, 3q, 6qcen-q22,
7cen-q33, 8q, 11q13, 14q, 18p
17cen-q21, 20cen-q12 12 9q31 11
17 2q22–q32, 3q, 4cen-q31, 8q, 11p14–q13 5p, 12p13-pter, 19q 8 1q31, 6q22–q24, 7q31.1–31.3, 18p 9
18 1q21.1-qter, 2q21.3–32.1, 3q21-qter,
5p15.1-pter, 8q22.2–24.2, 15q15–26.1,
18p11.31-pter
2p14–16, 6p11.2-pter, 7pcent-15.3,
7q33-qter, 7q21.1–21.3, 12p,
16q12.1–23
14 7p15.3–p21, 7q31.1–31.3, 11pcent-13,
14qcent–13
11
19 2pcent-11.2, 2p13-pter, 3q23-qter, 5p,
9p21–p22, 9q22.2–q33, 14q24.1–q32,
17p, 17qcent-q23, 19pcent-p13.1
2q24.3–q32.1, 6p11.2–p21.1,
7q21.3–q31.1, 7q36, 11qcent-q13.3,
12pcent-12.1, 22qcent-13.2
17 1q21–23, 7pcent-p14, 10p11.1–p11.2, 10p15,
12qcent-q21.1, 14qcent-q21, 18p
17
20 2q24.1–q32, 3qcent-13.1, 7p14-pter,
7q11.23–q22, 12p13.3, 13q33,
14q24.2–q32.1, 17p
3q28, 4q21.2–q24, 5p,
13q12.1–q12.2, 18p11.31-pter
13 1p32.1, 1q21.1–q21.3, 11qcent-q13.3,
19p13.3-pter, 19qcent-q13.1, 22q13.2
14
21 1q31, 3q21–q27, 5p, 8q22.1–q24.1,
11q12–q14.2, 12p
7q21.2–q21.3 7 14q, 16p13.3, 16q 9
22 1q25–32.1, 3q, 7p15.2-pter, 8q23–q24.2,
9q33–34.2, 12p, 16q23
1q21.3–22, 7q, 11qcent-q13.2,
17q23, 18p11.31-pter, 19p,
19qcent-q13.2, 20q13.1
15 1p36.3-pter, 10p15-pter, 11p15.5-pter,
16p13.3, 19q13.4-qter, 21q22.2, 22q13.2
14
23 1qcen-q31, 5p, 8q22.2–q24.2, 12p,
12qcent-q21.3, 14q32.2, 17q21.2–q24,
19p13.3-pter
1p32.1–p32.3, 3q35–q36, 9q34.2 11 2pcen-p16, 2q21.2–q31, 3p11–p12,
3q21–q28, 6pcen-p12, 6q, 7q21.1,
7q31.1–q35, 9p23-pter, 10p15,
15q21.1–q25, 18p, 22q13.2–q13.3
16
PT¼primary tumour; LNM¼lymph node metastasis.
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that included some of the patients analysed previously also
found an association between deletions of 10q, 11p and 11qter
and node-positive PT. Whether these differences are simply
due to the relatively small number of tumours studied or truly
reflect the complex genetic make-up of HNSCC remain to be
elucidated.
Although the technique of CGH has limitations, that is, balanced
translocations, rearrangements and/or ploidy change cannot be
recognised, and no obvious genetic metastatic signature could be
identified; the CGH data from all three studies do confirm
the clonal relationship of the primary and LNM. Furthermore,
CGH remains a useful tool to guide the application of higher-
resolution techniques such as loss of heterozygosity studies
and mutational analysis, ultimately speeding up the identification
of the critical genes involved in HNSCC tumorigenesis. In the
future, once such genes have been categorised, new technologies
like DNA microarrays, which simultaneously analyse the
expression of vast repertoires of genes in individual tumours, will
be used to predict the clinical characteristics of a patient’s
tumour at the time of diagnosis allowing the optimisation of the
treatment regimen.
Table 4 Chromosomal locations of DNA loss in individual patients
ID
no. Common deletions PT, unique deletions
Total no.
deletions LNM, unique deletions
Total no.
deletions
1 3p, 4p, 5q, 13q12–13 1p34-pter, 2q37-qter, 10p, 11q14-qter, 17p 9 1p2, 2q24–32, 4qcent-q28, 6qcen-q23, 9p,
14q21–23, 18q, 21
12
2 4q26-qter, 5q14–23, 13q2-qter 2q37, 3p, 6q26-qter, 8p, 10q25-qter,
11q21-qter, 18q22-qter, 21
11 3
3 1p33-pter, 2p23-pter, 3p, 4p14–15,
4q26-qter, 5q13, 6p22-pter, 8p,
9pter-q22.1, 10, 11q23-qter,
13q12–13, 13q22-qter, 17p,
18q, 19q
16 9q22.3, 16q 18
4 8p21-pter, 10q26 3p24-pter, 11q24-qter 4 2
5 3p, 11q23-qter 2 2q37, 4p15.3-qter, 5q34-qter, 7q31.3-qter,
12q22-qter
7
6 1p32–pter, 9q34, 17p 3p2-pter, 4p15.3-pter, 5q34-qter, 10,
11p15-pter, 14q31-qter, 16q, 21
11 12q24-qter, 16p, 17q24-qter, 19, 22 6
7 1p34-pter 2p25, 2q37, 3p23-pter, 4p15-pter,
5p15.1-pter, 5q35, 8q24.3-qter, 10q25-qter,
11p14, 11q23-qter, 18q22-qter
12 9q34, 17, 19, 20q13-qter, 22 6
8 3p, 5q31-qter, 7q32-qter, 8p 2q37, 6p23-pter, 11p14-pter, 18q22-qter, 21 9 4p16 5
9 2q37.2-pter, 4p16-pter, 5q35.1-qter,
12q24.31-qter, 17q25-qter
1p36-pter, 10p13-pter, 14q32.1-qter,
19q13.4-qter
9 7q36-qter, 10q26-qter 7
10 1p35-pter, 9q32-qter, 17q23-qter,
19p, 22q
5q34-qter, 16p, 17p, 19q 9 4p15.3-pter, 12q24.2-qter, 21q 8
11 5q35, 6p24-pter, 11p15, 18q22-qter, 21 5 1p35-pter, 9q34, 17p13 3
12 3p, 13q, 14q22-qter 8p22-pter, 11q14-qter, 16p12-cen 6 2p32, 4qcen-q28, 5q13, 5q21–23, 6q12–q22,
9p23
9
13 5q33-qter, 8p, 11q22-qter, 19p, 22 3p14–p25, 7q31.3-qter, 18q12-qter,19q, 21 10 1p33–35, 4p16, 6q25-qter, 16p, 16q22-qter, 17p,
20q12–13.1
12
14 1p31.1–31.2, 3p, 6q24-qter, 9p, 9q32-
qter, 11p, 13q14, 14q21-qter, 15q, 16
8p, 11q21–23, 21 13 4q33-qter, 10 12
15 6q26 1 7q36 1
16 1p32-pter, 2q35-qter, 4p15.3-pter,
8p, 9p23-pter, 9q34-qter,
10q25-qter, 11p15-pter, 13q31-qter,
16p12-pter, 17p, 17q24-qter,
18q21-qter, 19p, 21, 22
3p25-pter, 5q34-qter, 10p14, 11q23-qter,
16q22-qter
21 4q33-qter, 5p15.1-pter, 7p21-pter 19
17 3p, 5q13, 10, 11q23, 13 5q34-qter, 7q32-qter, 12q24-qter, 16p,
16q22-qter, 21
11 1p36-pter, 4p15, 17q24-qter, 20p, 22 10
18 1p31.1-pter, 2q36-pter, 4q, 8p21–22,
11p15-pter, 17q, 21q22.1–22.2
2p25.1-pter, 5q33.2-qter, 7q33-qter,
10p, 12q24.2
13 4p15.2-pter, 5q13.1–13.3, 6q25.1–26,
14q23-qter, 16q22–23, 19p13.1-pter
14
19 1p13.2-pter, 2q35–37, 3p13–21.1,
3p21.3-pter, 4p13-pter, 4q28–4q34,
5q12-qter, 8p12-pter, 13q22–33,
20q12–q13.1
1q23,1q42, 2q21, 2q35–37, 6p22.3–p24,
18q11.2–q22, 20p11.2–p12,
21q11.2–q21
18 4q22–q23, 6q16.3–q21, 7q11.23–q21.1,
9p23-pter, 10q, 11q22.3–q24, 15q13–q26,
19q13.1–q13.2
18
20 6p22.3-pter, 10qcent-q21.2 2q34 3 3p, 5q, 11q22.3–q24, 13q14.1-pter 6
21 1p13.3–31.1, 3p13-pter,
4p15.1–15.2, 6q21–26, 13q,
18q12.2–22, 21qcent-q22.2
7 9p12, 9p21–23, 15q, 19p13.1-pter 11
22 4q31–q34, 15q12–q14 1p22.1–p31.1, 4p12–p15.2, 13q21.1 5 16p11.2–p14 3
23 3p13-pter, 4p15.1-pter,
4q31.2–q34, 7p
9p12 5 1p36.2, 2q33–q37.2, 5q23.1–q34, 8q13,
9q21.1–q33, 10qcen-q25.3, 11p12-pter,
11qcen-13.3, 11q22.1–q22.3, 13qcent-q13,
13q31–q33, 14q22–q23, 16q12.1–q23,
17p11.2-pter, 18q12.2–q22, 20p11.2–p12,
20q11.2–q13.2
20
PT¼primary tumour; LNM¼lymph node metastasis.
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Figure 1 Ideogram to show the location of all the deletions and gains found in all 23 primary tumours. Lines drawn to the left of the ideogram represent
the location of regions of deletion or loss. Lines drawn to the right represent the location of gains or amplifications of chromosomal material.
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Figure 2 Ideogram to show the location of all the deletions and gains found in all 23 metastatic lymph node samples. Lines drawn to the left of the
ideogram represent the location of regions of deletion or loss. Lines drawn to the right represent the location of gains or amplifications of chromosomal
material.
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